Physician profile
Roger Juarez
NPI 1154587939
$2,561.42
in general payments reported to CMS, 2019-2025
18 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $359 · 2021: $167 · 2022: $607 · 2023: $183 · 2024: $540 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $495.38 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $420.29 | 2019-2025 | Eysuvis, Rocklatan, Total30 |
| Notal Vision, INC. | $267.36 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $241.22 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $239.12 | 2019-2021 | |
| Coopervision INC. | $192.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $129.31 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $118.98 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $84.81 | 2019-2023 | Cequa |
| Harrow Eye, LLC | $67.39 | 2025 | Vevye |
| Carl Zeiss Meditec, INC. | $60.36 | 2019 | |
| Genentech USA, INC. | $59.07 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $58.41 | 2022-2025 | Acuvue |
| Abbvie INC. | $33.18 | 2024 | |
| Dompe US, INC. | $29.72 | 2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.38 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $20.61 | 2025 | Xdemvy |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Juarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.